These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28793923)

  • 1. Concurrent antitumor and bone-protective effects of everolimus in osteotropic breast cancer.
    Browne AJ; Kubasch ML; Göbel A; Hadji P; Chen D; Rauner M; Stölzel F; Hofbauer LC; Rachner TD
    Breast Cancer Res; 2017 Aug; 19(1):92. PubMed ID: 28793923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone-protective and anti-tumor effect of baicalin in osteotropic breast cancer via induction of apoptosis.
    Wang B; Huang T; Fang Q; Zhang X; Yuan J; Li M; Ge H
    Breast Cancer Res Treat; 2020 Dec; 184(3):711-721. PubMed ID: 32939591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
    Suvannasankha A; Chirgwin JM
    Breast Cancer Res; 2014; 16(6):484. PubMed ID: 25757219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
    Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
    Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro.
    Yamaguchi M; Zhu S; Weitzmann MN; Snyder JP; Shoji M
    Mol Cell Biochem; 2015 Mar; 401(1-2):1-10. PubMed ID: 25416449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells.
    Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F
    BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.
    Mercatali L; Spadazzi C; Miserocchi G; Liverani C; De Vita A; Bongiovanni A; Recine F; Amadori D; Ibrahim T
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27809291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
    Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
    Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis.
    Yamaguchi M; Zhu S; Zhang S; Wu D; Moore TM; Snyder JP; Shoji M
    Cell Tissue Res; 2014 Jul; 357(1):245-52. PubMed ID: 24723227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gentian violet inhibits MDA-MB-231 human breast cancer cell proliferation, and reverses the stimulation of osteoclastogenesis and suppression of osteoblast activity induced by cancer cells.
    Yamaguchi M; Vikulina T; Weitzmann MN
    Oncol Rep; 2015 Oct; 34(4):2156-62. PubMed ID: 26260090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
    Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
    J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G
    Cancer Res; 2007 Sep; 67(18):8742-51. PubMed ID: 17875715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coenzyme q10 regulates osteoclast and osteoblast differentiation.
    Moon HJ; Ko WK; Jung MS; Kim JH; Lee WJ; Park KS; Heo JK; Bang JB; Kwon IK
    J Food Sci; 2013 May; 78(5):H785-891. PubMed ID: 23582186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.
    Siclari VA; Mohammad KS; Tompkins DR; Davis H; McKenna CR; Peng X; Wessner LL; Niewolna M; Guise TA; Suvannasankha A; Chirgwin JM
    Breast Cancer Res; 2014 Dec; 16(6):458. PubMed ID: 25439669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
    Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitory effects of low intensity pulsed ultrasound on osteoclastogenesis induced in vitro by breast cancer cells.
    Carina V; Costa V; Pagani S; De Luca A; Raimondi L; Bellavia D; Setti S; Fini M; Giavaresi G
    J Exp Clin Cancer Res; 2018 Aug; 37(1):197. PubMed ID: 30126457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
    Hadji P; Coleman R; Gnant M
    Crit Rev Oncol Hematol; 2013 Aug; 87(2):101-11. PubMed ID: 23838481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
    Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
    Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.